InvestorsHub Logo
Followers 4
Posts 929
Boards Moderated 0
Alias Born 08/15/2006

Re: XenaLives post# 535

Wednesday, 02/08/2017 4:24:59 PM

Wednesday, February 08, 2017 4:24:59 PM

Post# of 21536
I don't think I've ever said they would get approval out of this trial.

But you never know...Sarepta got approval for it's drug in a small-n trial (10 patients) in a deadly disease (Duchenne Muscular Dystrophy). :)

Seriously, though, I don't think it will be possible. Too many unanswered questions: treatment duration, dosing, manufacturing, etc.

Still, the upcoming phase 2b results, if we see efficacy and safety, could launch share price significantly.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News